Kenya Digital Therapeutics Market Analysis

The Kenya Digital Therapeutics Market size stood at around xx Bn in 2023 and is projected to reach US $xx Bn by 2033, exhibiting a CAGR of xx% during the forecast period.

The Kenya Digital Therapeutics Market Analysis Executive Summary

DTx is any form of therapeutic intervention that entails comprehensible and evidence-founded software applications capable of preventing, managing, or treating disease. While there is a multitude of wellness apps, DTx is designed with clinical evidence and most of them need approval, like a drug. The global environment for digital therapeutics is gradually changing, although it has gradually gained recognition and noted its efficacy for chronic diseases, mental illnesses, and addictive disorders. 

A paper suggest that the need for Delivered-to-Use (DTx) is informed by a desire of diverse more cost and effective models of healthcare practice especially in the context of the COVID-19 crisis that acted as a catalyst for enhanced uptake of digital health solutions. A survey from the Digital Therapeutics Alliance shows that the uptake of DTx products has risen and current statistics show more than fifty products have been cleared for approval in the U. S and Europe. Widely acceptance is also on the rise due to awareness of health caregivers and insurance issuers about the impact that DTx can provide to patients in terms of engagement and compliance with recommended regimens. Available literature indicates that implementing DTx models into healthcare environments can produce better patient outcomes and save on costs thus proving themselves as an element of more contemporary healthcare frameworks and policies. 

Market Size and Key Findings    

Market Dynamics

Market Growth Drivers

DTx acceptance, increases because they enable patient engagement and better health outcomes. Studies have shown that there are huge potential benefits of using DTx especially in the area of chronic illness and mental health through the individualised treatment solutions that also puts the patient at the centre of treatment. For instance, a research in Digital Medicine revealed that there was a positive impact of DTx when it comes to the adherence to treatment plans and clinical outcomes, especially for patients with diabetes and depression. Also, as we see DTx being more actively integrated into the clinical practices and the stakeholders becoming more aware of the clinical benefits of DTx, they have gained much acceptance and usage in different healthcare segments

Opportunity

There is new entrants are coming into the domain, pharma companies are partnering with digital therapeutic companies with for example Boehringer-Ingelheim partnering with Click Therapeutic for a treatment of schizophrenia. Even the existing organizations such as the FDA are also easing their approval procedures for the categories of products referred to as digital therapeutics, which is quite vital for market expansion

Market Restraints

Several factors explain why digital therapeutics are not commonly embraced in today’s society. Another critical issue is the relative ignorance of the HCP community about DTx’s effectiveness and clinical evidence. Similarly in an analysis conducted for the Psychiatric Times , clinicians revealed concern as they partly questioned the acceptance of DTx in to their practice especially given the lack of information from randomized controlled trials. Moreover, there are regulatory and reimbursement barriers that act as major concerns because most of the times the payer needs to see significant proof of cost-effectiveness before making payments. Issues regarding data privacy and compatibility with the current EHR systems are the other issues that have made the adoption of these systems challenging

Competitive Landscape for Digital Therapeutics Market in Kenya

Key Players

• Pear Therapeutics
• Omada Health
• Akili Interactive
• Click Therapeutics
• Propeller Health
• Welldoc
• Mango Health
• Biofourmis
• Proteus Digital Health
• Voluntis

Recent Developments:

October 2023, Better Therapeutics, Inc. has launched AspyreRx, the first cognitive behavioral therapy (CBT) app aimed at treating adults with type 2 diabetes (T2D)

July 2022, AmerisourceBergen has launched DTx Connect, a comprehensive platform designed to streamline the ordering, dispensing, and fulfillment of physician-prescribed digital therapeutics and diagnostics, enhancing patient access.

Mergers and Acquisitions

February 2023, JOLLY GOOD Inc. and TEIJIN LIMITED announced a partnership to develop virtual reality solutions in this market for major depressive disorders

August 2022, Akili Inc., the maker of a video game-like digital therapeutic for children with ADHD, announced the merger with a special-purpose acquisition company Social Capital Suvretta Holdings Corp

Healthcare Policies and Regulatory Landscape for Digital Therapeutics Market in Country Name)

Policy changes and Reimbursement scenario

The encouraging regulatory changes across healthcare policies for digital therapeutics especially in the US are progressive; Medicare has put forward the new codes in the 2025 Medicare Physician Fee Schedule to cover reimbursement for the digital mental health treatments including apps that offer cognitive behavioural therapy. This is progressive to digital therapeutics companies since it allows billing for the time clinicians spend on services concerning such digital treatments and only if the technologies are FDA-approved. Thus, different European countries’ regulatory bodies are gradually starting to grasp the concept of digital therapeutics’ incorporation into their healthcare systems. Germany is still building up structures to support DTx, but France and Belgium, for example, are more advanced in this respect, while EMA is working on the guidelines for the assessment and approval of digital health technologies. Nevertheless, one of the key issues is reimbursement because most of the payers are reluctant to reimburse digital therapeutics unless the cost-effectiveness of these interventions is documented.